

1 **Heterogeneity and transmissibility in shedding SARS-CoV-2 via droplets and aerosols**

2

3 Paul Z. Chen, Niklas Bobrovitz, Zahra Premji, Marion Koopmans, David N. Fisman, Frank X.

4 Gu

5

6 Frank X. Gu

7 Email: f.gu@utoronto.ca

8

9

10 **This PDF file includes:**

11 Supplementary Methods

12 Figures S1 to S15

13 Tables S1 to S10

14 SI References

15 **Supplementary Methods**

16 **Search strategy, selection criteria and data collection.** The search included papers that (i)
17 reported positive, quantitative measurements (copies/ml or an equivalent metric) of SARS-CoV-
18 2, SARS-CoV-1 or A(H1N1)pdm09 in human respiratory specimens (ETA, NPA, NPS, OPS,
19 POS and Spu) from COVID-19, SARS or A(H1N1)pdm09 cases; (ii) reported data that could be
20 extracted from the infectious periods of SARS-CoV-2 (defined as -3 to +10 DFSO for
21 symptomatic cases and 0 to +10 days from the day of laboratory diagnosis for asymptomatic
22 cases), SARS-CoV-1 (defined as 0 to +20 DFSO or the equivalent asymptomatic period) or
23 A(H1N1)pdm09 (defined as -2 to +9 DFSO for symptomatic cases and 0 days to +9 days from
24 the day of laboratory diagnosis for asymptomatic cases); and (iii) reported data for two or more
25 cases with laboratory-confirmed COVID-19, SARS or A(H1N1)pdm09 based on World Health
26 Organization (WHO) case definitions. Quantitative specimen measurements were considered
27 after RNA extraction for diagnostic sequences of SARS-CoV-2 (*Ofr1b*, *N*, *RdRp* and *E* genes),
28 SARS-CoV-1 (*Ofr1b*, *N* and *RdRp* genes) and A(H1N1)pdm09 (*HA* and *M* genes).

29 Studies were excluded, in the following order, if they (i) studied an ineligible disease; (ii)
30 had an ineligible study design, including those that were reviews of evidence (e.g., scoping,
31 systematic or narrative), did not include primary clinical human data, reported data for less than
32 two cases due to an increased risk of selection bias, were incomplete (e.g., ongoing clinical
33 trials), did not report an RNA extraction step before measurement or were studies of
34 environmental samples; (iii) reported an ineligible metric for specimen concentration (e.g.,
35 qualitative RT-PCR or cycle threshold [Ct] values without calibration included in the study); (iv)
36 reported quantitative measurements from an ineligible specimen type (e.g., blood specimens,
37 pooled specimens or self-collected POS or Spu patient specimens in the absence of a healthcare

38 professional); (v) reported an ineligible sampling period (consisted entirely of data that could not
39 be extracted from within the infectious period); or (vi) were duplicates of an included study (e.g.,
40 preprinted version of a published paper or duplicates not identified by Covidence). We included
41 data from control groups receiving standard of care in interventional studies but excluded data
42 from the intervention group. Patients in the intervention group are, by definition, systematically
43 different from general case populations because they receive therapies not being widely used for
44 treatment, which may influence virus concentrations. Interventional studies examining the
45 comparative effectiveness of two or more treatments were excluded for the same reason. Studies
46 exclusively reporting semiquantitative measurements (e.g., Ct values) of specimen concentration
47 were excluded, as these measurements are sensitive to batch and instrument inconsistencies and,
48 without proper calibration, cannot be compared on an absolute scale across studies (36).

49 We searched, without the use of filters or language restrictions, the following sources:
50 MEDLINE (via Ovid, 1946 to 7 August 2020), EMBASE (via Ovid, 1974 to 7 August 2020,
51 Cochrane Central Register of Controlled Trials (via Ovid, 1991 to 7 August 2020), Web of
52 Science Core Collection (including: Science Citation Index Expanded, 1900 to 7 August 2020;
53 Social Sciences Citation Index, 1900 to 7 August 2020; Arts & Humanities Citation Index, 1975
54 to 7 August 2020; Conference Proceedings Citation Index - Science, 1990 to 7 August 2020;
55 Conference Proceedings Citation Index - Social Sciences & Humanities, 1990 to 7 August 2020;
56 and Emerging Sources Citation Index, 2015 to 7 August 2020), as well as medRxiv and bioRxiv
57 (both searched through Google Scholar via the Publish or Perish program, to 7 August 2020).
58 We also gathered studies by searching through the reference lists of review articles identified by
59 the database search, by searching through the reference lists of included articles, through expert
60 recommendation (by Epic J. Topol, Akiko Iwasaki and A. Marm Kilpatrick on Twitter) and by

61 hand-searching through journals (*Nature*, *Nat. Med.*, *Science*, *NEJM*, *Lancet*, *Lancet Infect. Dis.*,
62 *JAMA*, *JAMA Intern. Med.* and *BMJ*). A comprehensive search was developed by a librarian,
63 which included subject headings and keywords. The search strategy had 3 main concepts
64 (disease, specimen type and outcome), and each concept was combined using the appropriate
65 Boolean operators. The search was tested against a sample set of known articles that were pre-
66 identified. The line-by-line search strategies for all databases are included in *SI Appendix*, Tables
67 S1 to S5. The search results were exported from each database and uploaded to the Covidence
68 online system for deduplication and screening.

69 Two authors independently screened titles and abstracts, reviewed full texts, collected data
70 and assessed risk of bias via Covidence and a hybrid critical appraisal checklist based on the
71 Joanna Briggs Institute (JBI) tools for case series, analytical cross-sectional studies and
72 prevalence studies (58-60). To evaluate the sample size in a study, we used the following
73 calculation:

$$74 \quad n^* = \frac{z^2 \sigma}{d^2}, \quad (S1)$$

75 where n^* is the sample size threshold, z is the z-score for the level of confidence (95%), σ is the
76 standard deviation (assumed to be $3 \log_{10}$ copies/ml, one quarter of the full range of rVLs) and d
77 is the marginal error (assumed to be $1 \log_{10}$ copies/ml, based on the minimum detection limit for
78 qRT-PCR across studies) (61). The hybrid JBI critical appraisal checklist is shown in *SI*
79 *Appendix*, Table S10. Studies were considered to have low risk of bias if they met the majority of
80 the items, indicating that the estimates were likely to be correct for the target population.
81 Inconsistencies were resolved by discussion and consensus.

82 The search found 29 studies for COVID-19 (21, 38, 42, 43, 53, 62-85), 8 studies for SARS
83 (44, 86-92) and 27 studies for A(H1N1)pdm09 (93-119) and data were collected from each

84 study. For preprinted studies that were published as journal articles before the submission date of
85 this manuscript, we included the citation for the journal article. Descriptive statistics on
86 quantitative specimen measurements were collected from confirmed cases directly if reported
87 numerically or using WebPlotDigitizer 4.3 (<https://apps.automeris.io/wpd/>) if reported
88 graphically. Individual specimen measurements were collected directly if reported numerically
89 or, when the data were clearly represented, using the tool if reported graphically. We also
90 collected the relevant numbers of cases, types of cases, pharmacotherapies, volumes of transport
91 media, numbers of specimens and DFSO (for symptomatic cases) or day relative to initial
92 laboratory diagnosis (for asymptomatic cases) on which each specimen was taken. Hospitalized
93 cases were defined as those being tested in a hospital setting and then admitted. Non-admitted
94 cases were defined as those being tested in a hospital setting but not admitted. Community cases
95 were defined as those being tested in a community setting. Symptomatic, presymptomatic and
96 asymptomatic infections were defined as in the study. Based on rare description in contributing
97 studies, paucisymptomatic infections, when described, were included with symptomatic ones.
98 Pediatric cases were defined as those below 18 years of age or as defined in the study. Adult
99 cases were defined as those 18 years of age or higher or as defined in the study.

100

101 **Viral kinetics.** For initial parameterization, eqs. (4)-(6) were simplified according to a quasi-
102 steady state approximation (120) to

103
$$\frac{dT}{dt} = -\beta TV \quad (S2)$$


104
$$\frac{dV}{dt} = rTV - \delta V, \quad (S3)$$

105 where $r = p\beta/c$, for a form with greater numerical stability. The system of differential equations
106 was fitted on the mean estimates of SARS-CoV-2 rVL between -2 and 10 DFSO using the
107 entirety of individual sample data in units of copies/ml. Numerical analysis was implemented
108 using the Fit ODE app in OriginPro 2019b (OriginLab Corporation, Northampton,
109 Massachusetts, USA) via the Runge-Kutta method and initial parameters V_0 , I_0 and T_0 of 4
110 copies/ml, 0 cells and 5×10^7 cells, respectively, for the range -5 to 10 DFSO. The analysis was
111 first performed with eqs. (S2)-(S3). These output parameters were then used to initialize final
112 analysis using eqs. (3)-(5), where the estimates for β and δ were input as fixed and variable
113 parameters, respectively. The fitted line and its coefficient of determination (r^2) were presented.

114 To estimate the average incubation period, we extrapolated the kinetic model to 0 log₁₀
115 copies/ml pre-symptom onset. To estimate the average duration of shedding, we extrapolated the
116 model to 0 log₁₀ copies/ml post-symptom onset. Unlike in experimental studies, this estimate for
117 duration of shedding was not defined by assay detection limits. To estimate the average DFSO
118 on which SARS-CoV-2 concentration reached diagnostic levels, we extrapolated the model pre-
119 symptom onset to the equivalent of 1 and 3 log₁₀ copies/ml (chosen as example assay detection
120 limits) in specimen concentration for NPSs immersed in 1 ml of transport media, as described by
121 the dilution factor estimation above. The average time from respiratory infection to reach
122 diagnostic levels was then calculated by subtracting these values from the estimated average
123 incubation period. Notably, the extrapolated time for SARS-CoV-2 to reach diagnostic
124 concentrations in the respiratory tract should be validated in tracing studies, in which contacts
125 are prospectively subjected to daily sampling.


126

127 **Calculation of rate profiles of expelled particles.** Rate profiles (particles/min or
128 particles/cough) were calculated based on the corrected normalized concentration ($dC_n/d\log D_p$,
129 in units of particles/cm³) at each discrete particle size, normalization (32 size channels per
130 decade) for the aerodynamic particle sizer used, unit conversion (cm³ to L) and the sample flow
131 rate (1 L/min). For coughing, the calculation assumed that participants coughed 10 times in the
132 30-s sampling interval. To determine the corrected normalized concentrations for breathing, we
133 used a particle dilution factor of 4 and evaporation diameter factor of 0.5 (55). Breathing was
134 taken to expel negligible quantities of larger respiratory particles based on the bronchiolar fluid
135 film burst mechanism (55). To account for intermittent breathing while talking and singing, the
136 rate profiles for these activities included the contribution of aerosols expelled by breathing.




137

138 **Fig. S1.** Meta-regression between dispersion in SARS-CoV-2, SARS-CoV-1 and
 139 A(H1N1)pdm09 transmissibility and heterogeneity in rVL. Meta-regression of dispersion
 140 parameter (k) with the standard deviation (SD) of respiratory viral loads (rVLs) from all
 141 contributing studies (Pearson's $r = -0.26$). Pooled estimates of k were determined from the
 142 literature. Blue, red and yellow circles denote A(H1N1)pdm09 ($N = 27$), COVID-19 ($N = 29$)
 143 and SARS ($N = 8$) studies, respectively. Circle sizes denote weighting in the meta-regression.
 144 The P -value was obtained using the meta-regression slope t -test.




146 **Fig. S2.** Meta-analysis of rVLs of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09
147 during the infectious period. Random-effects meta-analyses comparing the expected respiratory
148 viral loads (rVLs) for COVID-19, SARS and A(H1N1)pdm09 cases during the infectious period.
149 Quantitative specimen measurements were used to estimate rVLs, which refer to virus
150 concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community
151 (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As).
152 Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal
153 swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum
154 (Spu). Dashes denote case numbers that were not obtained. Box sizes denote weighting in the
155 overall estimates. Between-study heterogeneity was assessed using the P -value from Cochran's
156 Q test and the I^2 statistic. References before 58 are listed in the main body. One-sided Welch's t -
157 tests compared the expected SARS-CoV-2 rVL with those of SARS-CoV-1 and A(H1N1)pdm09
158 (non-significance, $P > 0.05$).



159


160 **Fig. S3.** Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-2 rVL
 161 during the infectious period. Random-effects meta-analyses, based on the risk of bias of
 162 contributing studies, of the expected respiratory viral loads (rVLs) of COVID-19 cases during
 163 the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract.
 164 Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),
 165 symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal
 166 aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal
 167 swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Dashes denote case
 168 numbers that were not obtained. Box sizes denote weighting in the overall estimates. One-sided
 169 Welch's *t*-test for difference (non-significance, $P > 0.05$). Between-study heterogeneity was

170 assessed using the P -value from Cochran's Q test (non-significance, $P > 0.05$) and the I^2 statistic
171 ($I^2 < 30\%$ indicates low between-study heterogeneity). References before 58 are listed in the
172 main body.



173


174 **Fig. S4.** Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-1 rVL
 175 during the infectious period. Random-effects meta-analyses, based on the risk of bias of
 176 contributing studies, of the expected respiratory viral loads (rVLs) of SARS cases during the
 177 infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract. Case
 178 types: hospitalized (H), adult (A) and symptomatic (S). Specimen types: nasopharyngeal aspirate
 179 (NPA) and nasopharyngeal swab (NPS). Dashes denote case numbers that were not obtained.
 180 Box sizes denote weighting in the overall estimates. One-sided Welch's *t*-test for difference,
 181 non-significance ($P > 0.05$). Between-study heterogeneity was assessed using the *P*-value from
 182 Cochran's *Q* test (non-significance, $P > 0.05$) and the I^2 statistic ($I^2 < 30\%$ indicates low
 183 between-study heterogeneity). References before 58 are listed in the main body.



184


185 **Fig. S5.** Risk-of-bias sensitivity analysis of between-study heterogeneity for A(H1N1)pdm09
 186 rVL during the infectious period. Random-effects meta-analyses, based on the risk of bias of
 187 contributing studies, of the expected respiratory viral loads (rVLs) of A(H1N1)pdm09 cases
 188 during the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory
 189 tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),
 190 symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: nasopharyngeal
 191 aspirate (NPA), nasopharyngeal swab (NPS) and oropharyngeal swab (OPS). Dashes denote case
 192 numbers that were not obtained. Box sizes denote weighting in the overall estimates. References
 193 before 58 are listed in the main body. One-sided Welch's *t*-test for difference (non-significance,
 194 $P > 0.05$). Between-study heterogeneity was assessed using the *P*-value from Cochran's *Q* test

195 (non-significance, $P > 0.05$) and the I^2 statistic ($I^2 < 30\%$ indicates low between-study
196 heterogeneity).



197


198 **Fig. S6.** Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-2 rVL
199 for adult COVID-19 cases during the infectious period. Random-effects meta-analyses, based on
200 the risk of bias of contributing studies, of the expected respiratory viral loads (rVLs) of adult
201 (≥ 18 years old) COVID-19 cases during the infectious period. Quantitative rVLs refer to virus
202 concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community
203 (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As).
204 Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal
205 swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum
206 (Spu). Dashes denote case numbers that were not obtained. Box sizes denote weighting in the
207 overall estimates. References before 58 are listed in the main body. One-sided Welch's *t*-test for
208 difference (non-significance, $P > 0.05$). Between-study heterogeneity was assessed using the *P*-
209 value from Cochran's *Q* test (non-significance, $P > 0.05$) and the I^2 statistic ($I^2 < 30\%$ indicates
210 low between-study heterogeneity).



211

212 **Fig. S7.** Risk-of-bias sensitivity analysis of between-study heterogeneity for SARS-CoV-2 rVL
 213 for symptomatic/presymptomatic COVID-19 cases during the infectious period. Random-effects
 214 meta-analyses, based on the risk of bias of contributing studies, of the expected respiratory viral
 215 loads (rVLs) of symptomatic/presymptomatic (≥ 18 years old) COVID-19 cases during the
 216 infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract. Case
 217 types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P), symptomatic
 218 (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal aspirate (ETA),
 219 nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS)
 220 and sputum (Spu). Dashes denote case numbers that were not obtained. Box sizes denote
 221 weighting in the overall estimates. References before 58 are listed in the main body. One-sided
 222 Welch's *t*-test for difference (non-significance, $P > 0.05$). Between-study heterogeneity was


223 assessed using the P -value from Cochran's Q test (non-significance, $P > 0.05$) and the I^2 statistic
224 the I^2 statistic ($I^2 < 30\%$ indicates low between-study heterogeneity).




225

226 **Fig. S8.** Respiratory viral loads for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 best
 227 conform to Weibull distributions. (A to D) Normal ($P \leq 0.01$) (A), lognormal ($P \leq 0.01$) (B),
 228 gamma ($P \leq 0.005$) (C) and Weibull ($P > 0.10$, not significant [NS]) (D) probability plots for

229 individual sample data of SARS-CoV-2 rVLs across days from symptom onset in the systematic
230 dataset ($N = 941$ samples from $N = 20$ studies). (*E* to *H*) Normal ($P > 0.05$, NS) (*E*), lognormal
231 ($P \leq 0.01$) (*F*), gamma ($P > 0.05$, NS) (*G*) and Weibull ($P > 0.10$, NS) (*H*) probability plots for
232 individual sample data of SARS-CoV-1 rVLs in the systematic dataset ($N = 303$ samples from N
233 $= 5$ studies). (*I* to *L*) Normal ($P \leq 0.01$) (*I*), lognormal ($P \leq 0.01$) (*J*), gamma ($P \leq 0.005$) (*K*) and
234 Weibull ($P > 0.10$, NS) (*L*) probability plots for individual sample data of A(H1N1)pdm09 rVLs
235 in the systematic dataset ($N = 512$ samples from $N = 10$ studies). These categories included only
236 rVL data from positive (above the detection limit) qRT-PCR measurements. The P -values were
237 determined using the modified Kolmogorov-Smirnov test for the goodness of fit of each
238 distribution. When the null hypothesis is accepted (NS at $P > 0.05$), the probability density
239 function cannot be rejected to describe the distribution of the data. Blue circles, black lines and
240 red lines represent individual sample data, expected distributions and 95% CIs, respectively. (*M*
241 to *O*) Histograms and fitted Weibull distributions of the above data for SARS-CoV-2 (*M*),
242 SARS-CoV-1 (*N*) and A(H1N1)pdm09 (*O*).




244 **Fig. S9.** Case heterogeneity in rVLs across viruses, COVID-19 subgroups and disease course. (*A*
245 to *C*) Estimated respiratory viral loads (rVLs) of SARS-CoV-2 (*A*), SARS-CoV-1 (*B*) and
246 A(H1N1)pdm09 (*C*) across case percentile (cp) throughout the infectious periods. (*D* to *G*)
247 Estimated SARS-CoV-2 rVLs for adult (*D*), pediatric (*E*), symptomatic/presymptomatic (*F*) and
248 asymptomatic (*G*) cases across cp throughout the infectious period. (*H* to *S*) Estimated SARS-
249 CoV-2 rVLs across cp on different days from symptom onset (DFSO) during the infectious
250 period. Earlier DFSO were excluded based on limited data. Data ranged between the 1st and 99th
251 cps. Sample numbers, distribution parameters and descriptive statistics are summarized in *SI*
252 *Appendix*, Table S7. Lines and bands represent estimates and 95% CIs, respectively.



253

254 **Fig. S10.** Kinetics of SARS-CoV-2 and airway epithelial cells during respiratory infection. (A
 255 and B) Estimated kinetics of uninfected (blue) and productively infected (red) airway epithelial
 256 cells (left axis) and SARS-CoV-2 (right axis) in the respiratory tract, as shown in linear (A) and
 257 logarithmic (B) scales.


258



259

260 **Fig. S11.** Likelihood of respiratory particles containing SARS-CoV-2 or A(H1N1)pdm09. (A to
 261 E) Estimated likelihood that droplets and aerosols contain viable SARS-CoV-2 when expelled by
 262 the 25th case percentile (cp) (A), mean (B), 65th cp (C), 80th cp (D) or 90th cp (E) for COVID-19


263 cases during the infectious period. (*F* to *J*) Estimated likelihood that droplets and aerosols
264 contain viable A(H1N1)pdm09 when expelled by the 25th cp (*F*), mean (*G*), 65th cp (*H*), 80th cp
265 (*I*) or 90th cp (*J*) for A(H1N1)pmd09 cases during the infectious period. For higher no. of virions,
266 some likelihood curves were omitted to aid visualization. When the likelihood for 0 virions
267 approaches 0%, particles are expected to contain at least one viable copy. Lines and bands
268 represent estimates and 95% CIs, respectively, for estimated likelihoods.



269

270 **Fig. S12.** Rate profiles for particle expelled by respiratory activities. (A to D) Rate profiles of
 271 particles expelled while talking (A), singing (B), breathing (C) and coughing (D). (E)
 272 Comparison of the rate profiles of aerosol emission from singing and different amplitudes of
 273 talking. The rate profiles were calculated from the normalized concentrations in Johnson et al
 274 (55) (A, B, D and E) and Morawaska et al (56) (C) or collected from Asadi et al (57) (E).
 275 Dehydrated particle diameters were taken to be 0.5 times the hydrated diameter during

276 atomization. Breathing was taken to expel negligible quantities of larger particles based on the
277 bronchiolar fluid film burst mechanism.




278

279 **Fig. S13.** Heterogeneity in shedding SAR-CoV-2 via talking, breathing and coughing. (A to C)

280 Case heterogeneity in the total SARS-CoV-2 shedding rate (over all particle sizes) by talking at a

281 moderate amplitude (*A*), breathing (*B*) or coughing (*C*) for COVID-19 cases across the infectious
282 period. Earlier presymptomatic days were excluded based on limited data. Data represent
283 estimated rates for viable virus and range between the 1st and 99th cps. Lines and bands represent
284 estimates and 95% CIs, respectively.


285



286

287 **Fig. S14.** Heterogeneity in infectiousness for COVID-19 and A(H1N1)pmd09 cases during the
 288 infectious period. (A and B) Estimated time for a A(H1N1)pdm09 case to expel one virion by
 289 only aerosols (A) or either droplets or aerosols (B) by talking, singing, breathing or coughing. (C
 290 and D) Estimated time for a COVID-19 case to expel one SARS-CoV-2 virion via only aerosols

291 (C) or either droplets or aerosols (D) by talking, singing, breathing or coughing. Data represent
292 estimated times to expel viable virus and range between the 1st and 99th case percentiles (cps).
293 Vertical arrows depict the cp expected to shed 1 virion in 24 h (talking, singing or breathing) or
294 100 coughs. Lines and bands represent estimates and 95% CIs, respectively.



295

296 **Fig. S15.** Heterogeneity in shedding A(H1N1)pdm09 via droplets and aerosols. (*A* to *D*) Case
 297 heterogeneity in the total A(H1N1)pdm09 shedding rates while talking (*A*), singing (*B*),
 298 breathing (*C*) and coughing (*D*) during the infectious period. Data represent estimated rates for
 299 viable virus and range between the 1st and 99th cps. Lines and bands represent estimates and 95%
 300 CIs, respectively.

301 **Table S1.** Search strategy used for MEDLINE.

Database: Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 1946 to August 07, 2020	
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	exp Betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kf.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kf.
6	(pneumonia.tw,kf. Or exp pneumonia/) and (Wuhan or Hubei).tw,kf.
7	COVID-19.rx,px,ox. Or severe acute respiratory syndrome coronavirus 2.os.
8	exp Influenza A Virus, H1N1 Subtype/
9	(“A/H1N1*” or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 “2009”) or influenza A or swine flu).tw,kf.
10	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or “swab sample*” or “flocked swab*”).tw,kf.
12	Nasal cavity/vi
13	Sputum/vi
14	Nasopharynx/vi
15	Oropharynx/vi
16	*Saliva/vi
17	Pharynx/vi
18	(clinical adj2 (sample* or specimen*)).tw,kf.
19	(“RT-PCR” or “RTPCR” or “ddPCR” or “polymerase chain reaction”).tw,kf.
20	Influenza, Human/vi
21	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
22	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
23	11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24	10 and 23
25	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kf.
26	((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*).tw,kf.

27	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kf.
28	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kf.
29	Viral load/
30	Viral shedding/
31	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kf.
32	((test or diagnos*) adj2 sensitiv*).tw,kf.
33	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34	24 and 33
35	animals/ not humans/
36	34 not 35

302

303 **Table S2.** Search strategy used for EMBASE.

Database: Embase 1974 to 2020 August 06	
#	Searches
1	coronavirus infection/ or severe acute respiratory syndrome/
2	COVID 19/
3	coronavirus disease 2019/
4	severe acute respiratory syndrome coronavirus 2/ or SARS coronavirus 2/
5	SARS coronavirus/ or betacoronavirus/
6	“influenza a virus (h1n1)”/
7	2009 h1n1 influenza/ or “influenza a (h1n1)”/
8	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or Sudden acute respiratory syndrome*).tw,kw.
9	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
10	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
11	(covid or SARS or H1N1 or coronavirus).ox.
12	(“A/H1N1*” or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 “2009”) or influenza A or swine flu).tw,kw.
13	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14	nose smear/
15	smear/ or nose smear/ or sputum smear/
16	*sputum/
17	*nasopharynx/ or *pharynx/
18	throat culture/
19	saliva analysis/
20	*oropharynx/
21	exp nasopharyngeal aspiration/
22	real time polymerase chain reaction/ or real time reverse transcription polymerase chain reaction/ or reverse transcription polymerase chain reaction/
23	(clinical adj2 (sample* or specimen*)).tw,kw.
24	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or “swab sample*” or “flocked swab*”).tw,kw.
25	(“RT-PCR” or “RTPCR” or “ddPCR” or “polymerase chain reaction”).tw,kw.
26	*2009 H1N1 influenza/di or coronavirus disease 2019/di or Coronavirus infection/di

27	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28	13 and 27
29	virus load/
30	virus shedding/
31	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
32	((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
33	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.
34	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
35	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
36	((test or diagnos*) adj2 sensitiv*).tw,kw.
37	29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38	28 and 37
39	exp animal/ not human/
40	38 not 39

304

305 **Table S3.** Search strategy used for Cochrane Central.

Database(s): EBM Reviews – Cochrane Central Register of Controlled Trials July 2020	
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kw.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
6	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
7	exp Influenza A Virus, H1N1 Subtype/
8	(“A/H1N1*” or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 “2009”) or influenza A or swine flu).tw,kw.
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or “swab sample*” or “flocked swab*”).tw,kw.
11	Nasal cavity/
12	Sputum/
13	Nasopharynx/
14	Oropharynx/
15	*Saliva/
16	Pharynx/
17	(clinical adj2 (sample* or specimen*)).tw,kw.
18	(“RT-PCR” or “RTPCR” or “ddPCR” or “polymerase chain reaction”).tw,kw.
19	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
20	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
21	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22	9 and 21
23	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
24	((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*).tw,kw.
25	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.

26	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
27	Viral load/
28	Viral shedding/
29	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
30	((test or diagnos*) adj2 sensitiv*).tw,kw.
31	23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32	22 and 31

306

307 **Table S4.** Search strategy used for Web of Science Core Collection.

Web of Science Core Collection	
#	Searches
#1	<p>TOPIC: ((coronavirus* or “corona virus*” or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or “sars-cov*” or sarscov* or “Sars-coronavirus*” or “Severe Acute Respiratory Syndrome*” or “sudden acute respiratory syndrome*” or “2019-ncov*” or 2019nCov* or “2019-novel CoV” or corona or ((novel or new or nouveau) NEAR/2 (CoV or Pandemi*)) OR (pneumonia and (Wuhan or Hubei)) or “A/H1N1*” or H1N1* or pdm09 or ((influenza or virus or pandemic) NEAR/4 “2009”) or “influenza A” or “swine flu”))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#2	<p>TOPIC: (((respiratory NEAR/3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) NEAR/3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) NEAR/2 aspirat*) or NPA or ETA or (deep NEAR/4 saliva) or POS or “swab sample*” or “flocked swab*” or (clinical NEAR/2 (sample* or specimen*)) or “RT-PCR” or “RTPCR” or “ddPCR” or “polymerase chain reaction”))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#3	<p>TOPIC: ((“vir* load*” or “vir* shed*” or “vir* burden” or “vir* titer*” or “vir* titre*” or (vir* NEAR/2 count*) or ((copies or copy) NEAR/2 (ml or mls or milli* or microl*)) or ((RNA* or vir*) NEAR/2 concentration*) or (calibration NEAR/1 curve*) or (standard NEAR/1 curve*) or “ct value*” or “cycle threshold” or ((copies or copy) NEAR/2 test*) or ((copy or copies) NEAR/2 number*) or “copy/m*” or “copies/m*” or “copy/test*” or “copies/test*” or ((test or diagnos*) NEAR/2 sensitiv*))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#4	<p>#3 AND #2 AND #1</p> <p>Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES)</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>

308

309 **Table S5.** Search strategy used for medRxiv and bioRxiv.

medRxiv + bioRxiv (via Publish or Perish program)
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR “swine flu” OR COVID19 or SARS) AND (“copies/ml” OR “copy/ml” OR “viral load” OR “copies/test” OR “copy/test” OR “copies per ml” OR “copy per ml”) Publication name: MedRxiv
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR “swine flu” OR COVID19 or SARS) AND (“copies/ml” OR “copy/ml” OR “viral load” OR “copies/test” OR “copy/test” OR “copies per ml” OR “copy per ml”) Publication name: BioRxiv

310

311 **Table S6.** Characteristics of contributing studies.

Study*	Country	No. of cases included (no. of specimens)	No. of pediatric cases (no. of specimens)	No. of asymptomatic cases (no. of specimens)	Disease caused by virus	Case definition (WHO)	Pharmacotherapy (type) [†]	Individual data extracted (diluent volume reported) [‡]	Adjusted viral load [§] (type of specimen)	Weight, % (meta-analysis category)	Weight, % (meta-regression)	Risk of bias [¶]
Argyropoulos et al. (2020) (76)	USA	205 (205)	0	0	COVID-19	Confirmed	No	No (no)	Yes (NPS)	3.80 (V), 5.09 (A), 3.98 (S/Ps)	2.13	*****
Baggio et al. (2020) (74)	Switzerland	405 (405)	58 (58)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.84 (V), 5.14 (A), 13.9 (P), 3.88 (S/Ps)	4.20	*****
Fajnzylber et al. (2020) (65)	USA	- (31)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	3.45 (V), 4.62 (A), 3.76 (S/Ps)	0.32	*****
Han et al. (2020) (84)	South Korea	2 (8)	1 (6)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	2.53 (V), 4.06 (S/Ps)	0.08	*****
Han et al. (2020) (82)	South Korea	12 (27)	12 (27)	3 (7)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.43 (V), 17.5 (P), 4.10 (S/Ps), 14.3 (As)	0.28	*****
Hung et al. (2020) (70)	China	41 (310)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS, OPS, POS)	3.81 (V), 5.10 (A), 3.81 (S/Ps)	3.22	*****
Hurst et al. (2020) (81)	USA	133 (133)	54 (54)	52 (52)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.77 (V), 15.3 (P), 3.88 (S/Ps), 21.6 (As)	1.38	*****
Iwasaki et al. (2020) (71)	Japan	5 (5)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.53 (V), 3.37 (A), 4.12 (S/Ps)	0.05	***
Kawasuji et al. (2020) (85)	Japan	16 (16)	-	-	COVID-19	Confirmed	Yes (antivirals - type not reported)	Yes (no)	Yes (NPS)	3.15 (V)	0.18	*****
L'Huillier et al. (2020) (53)	Switzerland	23 (23)	23 (23)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.91 (V), 14.7 (P), 3.73 (S/Ps)	0.24	*****
Lavezzo et al. (2020) (42)	Italy	103 (110)	2 (3)	49 (49)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.77 (V), 5.03 (A), 11.57 (P), 3.57 (S/Ps), 21.8 (As)	1.14	*****
Lennon et al. (2020) (67)	USA	2,200 (2,200)	18 (18)	2,200 (2,200*)	COVID-19	Confirmed	No	No (yes)	Yes (NPS)	3.88 (V), 5.20 (A), 24.0 (As)	22.84	*****
Lucas et al. (2020) (75)	USA	24 (33)	0	0	COVID-19	Confirmed	Moderate and severe patients (tocilizumab)	Yes (yes)	Yes (NPS)	3.51 (V), 4.69 (A), 4.08 (S/Ps)	0.34	*****
Mitja et al. (2020) (77)	Spain	148 (296)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS)	3.81 (V), 5.10 (A), 3.93 (S/Ps)	3.07	*****

Pan et al. (2020) (83)	China	75 (104)	-	0	COVID-19	Confirmed	No	Yes (no)	Yes (OPS) No (Spu)	3.45 (V), 2.50 (S/Ps)	1.24	****
Peng et al. (2020) (63)	China	6 (6)	0	0	COVID-19	Confirmed	Yes (arbidol, lopinavir, ritonavir)	Yes (no)	Yes (OPS)	3.03 (V), 4.05 (A), 4.02 (S/Ps)	0.06	*****
Perera et al. (2020) (72)	China	- (36)	0	-	COVID-19	Confirmed	No	Yes (no)	Yes (NPA, NPS, OPS, Spu)	3.23 (V), 4.32 (A)	0.39	****
Shi et al. (2020) (69)	China	103 (103)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.87 (V), 5.18 (A), 4.34 (S/Ps)	1.07	*****
Shrestha et al. (2020) (68)	USA	171 (171)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.79 (V), 5.07 (A), 3.86 (S/Ps)	1.78	*****
To et al. (2020) (43)	China	23 (51)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (ETA, POS)	3.37 (V), 4.51 (A), 3.25 (S/Ps)	0.53	*****
van Kampen et al. (2020) (38)	The Netherlands	- (154)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, Spu)	3.80 (V), 5.09 (A), 4.10 (S/Ps)	1.60	*****
Vetter et al. (2020) (78)	Switzerland	5 (63)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.68 (V), 4.93 (A), 4.14 (S/Ps)	0.65	*****
Wölfel et al. (2020) (21)	Germany	9 (136)	0	1 (4)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	3.76 (V), 5.03 (A), 3.93 (S/Ps)	1.38	*****
Wyllie et al. (73)	USA	40 (42)	-	9 (9)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS)	3.55 (V), 4.75 (A), 4.00 (S/Ps), 18.3 (As)	0.44	*****
Xu et al. (2020) (80)	China	7 (14)	7 (14)	1 (1)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.40 (V), 17.3 (P), 4.1 (S/Ps)	0.15	*****
Yonker et al. (2020) (79)	USA	17 (17)	14 (14)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.58 (V), 9.79 (P), 3.28 (S/Ps)	0.18	*****
Zhang et al. (2020) (62)	China	9 (9)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	2.97 (V), 3.97 (A), 3.68 (S/Ps)	0.09	*****
Zheng et al. (2020) (66)	China	- (19)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (POS, Spu)	3.66 (V), 4.90 (A), 4.23 (S/Ps)	0.20	*****
Zou et al. (2020) (64)	China	14 (55)	0	1 (4)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.64 (V), 4.87 (A), 3.65 (S/Ps)	0.57	*****
Chen et al. (2006) (87)	China	154 (154#)	0	0	SARS	Confirmed	Yes (oseltamivir, broad-spectrum antibiotics, ribavirin)	Yes (no)	Yes (NPS)	14.0 (V)	1.59	*****
Chu et al. (2004) (88)*	China	11 (11)	0	0	SARS	Confirmed	No (control group)	Yes (yes)	Yes (NPS)	8.6 (V)	0.11	*****
Chu et al. (2005) (89)	China	57 (57)	0	0	SARS	Confirmed	No	Yes (yes)	Yes (NPA)	13.3 (V)	0.59	*****
Cheng et al. (2004) (91)	China	59 (59)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone,	Yes (yes)	Yes (NPA)	13.4 (V)	0.61	*****

Hung et al. (2004) (90)	China	60 (60)	0	0	SARS	Confirmed	prednisolone, methylprednisolone) Yes (ribavirin, hydrocortisone, prednisolone, methylprednisolone)	No (yes)	Yes (NPA)	13.5 (V)	0.62	*****
Peiris et al. (2003) (92)*	China	14 (42)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylprednisolone)	Yes (no)	Yes (NPA)	13.4 (V)	0.44	*****
Poon et al. (2003) (86)	China	40 (40)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	11.3 (V)	0.42	****
Poon et al. (2004) (44)	China	- (43)	0	0	SARS	Confirmed	-	No (yes)	Yes (NPA)	12.5 (V)	0.45	*****
Alves et al. (2020) (114)	Brazil	86 (86)	-	15 (15)	Influenza A(H1N1)pdm09	Confirmed	No	No (yes)	Yes (NPA, NPS, OPS)	3.7 (V)	0.89	****
Chan et al. (2011) (105)	China	58 (58)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (no)	Yes (NPA, NPS, OPS)	3.7 (V)	0.60	*****
Cheng et al. (2010) (115)	China	60 (60)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.62	*****
Cowling et al. (2010) (112)	China	45 (54)	22 (31)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (22 cases on oseltamivir)	Yes (yes)	Yes (NPS, OPS)	3.7 (V)	0.56	*****
Duchamp et al. (2010) (118)	France	209 (209)	209 (209)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	No (yes)	Yes (NPS)	3.8 (V)	2.17	****
Esposito et al. (2011) (109)	Italy	74 (282)	74 (282)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (yes)	Yes (NPS)	3.8 (V)	2.93	*****
Hung et al. (2010) (106)	China	87 (87)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (no)	Yes (NPA, NPS)	3.8 (V)	0.90	*****
Ip et al. (2016) (97)	China	17 (20)	7 (-)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.6 (V)	0.21	*****
Ito et al. (2012) (108)	Japan	34 (34)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (yes)	Yes (NPS)	3.7 (V)	0.35	****
Killingley et al. (2010) (103)	United Kingdom	12 (21)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.5 (V)	0.22	*****
Launes et al. (2012) (102)	Spain	47 (47)	47 (47)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.49	*****
Lee et al. (2011) (104)	China	48 (48)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.7 (V)	0.50	*****
Lee et al. (2011) (110)	Singapore	578 (578)	231 (231)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	3.8 (V)	6.00	*****

Li et al. (2010) (95)	China	581 (581)	522 (522)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (OPS)	3.8 (V)	6.03	*****
Li et al. (2010) (111)	China	27 (59)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (non-treated group)	No (no)	Yes (NPA, NPS, OPS)	3.7 (V)	0.61	*****
Loeb et al. (2012) (93)	Canada	97 (218)	-	- (17)	Influenza A(H1N1)pdm09	Confirmed	No	No (no)	Yes (NPS)	3.8 (V)	2.26	*****
Lu et al. (2012) (96)	China	13 (25)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	Yes (no)	Yes (NPS)	3.5 (V)	0.26	*****
Meschi et al. (2011) (99)	Italy	533 (533)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	3.8 (V)	0.92	*****
Ngaosuwankul et al. (2010) (116)	China	12 (33)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA, NPS, OPS)	3.6 (V)	0.34	*****
Rath et al. (2012) (98)	Germany	27 (41)	27 (41)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.7 (V)	0.43	*****
Suess et al. (2010) (94)	Germany	51 (129)	12 (-)	1 (1)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (no)	Yes (NPA, NPS, OPS)	3.8 (V)	1.34	*****
Thai et al. (2014) (107)	Vietnam	33 (123)	16 (-)	5 (28)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.8 (V)	1.28	*****
To et al. (2010) (113)	China	22 (22)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA, NPS, OPS)	3.4 (V)	0.23	*****
To et al. (2010) (117)	China	50 (50)	0	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, nebulized zanamivir)	No (no)	Yes (NPA, NPS)	3.6 (V)	0.52	*****
Watanabe et al. (2011) (119)	Japan	251 (251)	251 (251)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA)	3.8 (V)	2.61	*****
Wu et al. (2012) (100)	China	64 (89)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (yes)	Yes (NPS)	3.7 (V)	5.53	*****
Yang et al. (2011) (101)	China	251 (251)	-	0	Influenza A(H1N1)pdm09	Confirmed	N/A	No (yes)	Yes (OPS)	3.8 (V)	6.57	*****

*Data shown as "-" were not obtained from the paper or authors. References before 58 are listed in the main body.

†Responses of "no" for pharmacotherapy are based on no pharmacotherapy given to the patients as described explicitly or none reported in the study.

‡For studies reporting specimen measurements as individual sample data (either in numerical or graphical formats), the sample data was extracted for analysis.

§Specimen measurements were converted to rVLs based on the dilution factor for specimens immersed in transport media.

||Abbreviations for random-effects meta-analyses: virus meta-analysis (V), adult subgroup (A), pediatric subgroup (P), symptomatic/presymptomatic subgroup (S/Ps), asymptomatic subgroup (As).

¶The hybrid JBI Critical Appraisal Checklist was used, with more stars indicating lower risk of bias. Studies were considered to have low risk of bias if they met the majority of the items ($\geq 6/10$ items). Results from each study are shown in *SI Appendix*, Table S9.

#For these studies, 2,147 (Lennon et al.) and 134 (Chen et al.) individual specimen measurements were obtained for the individual sample datasets.

‡For Chu et al., only specimen measurements at 20 DFSO were collected, as 5-15 DFSO were specimens reported in Peiris et al.

321 **Table S7.** Descriptive parameters for respiratory viral loads based on individual sample data.

Category	n* (specimens)	n* (studies)	Weibull distribution parameters		Respiratory viral load, log ₁₀ copies/ml				
			Scale factor (95% CI)	Shape factor (95% CI)	Mean (95% CI) [†]	SD [†]	80 th percentile (95% CI) [‡]	90 th percentile (95% CI) [‡]	99 th percentile (95% CI) [‡]
SARS-CoV-2 (overall) [§]	3,834	26	7.01 (6.94-7.08)	3.47 (3.39-3.56)	6.29 (6.22-6.35)	2.04	8.04 (7.96-8.11)	8.91 (8.83-9.00)	10.88 (10.75-11.01)
SARS-CoV-1 (overall) [§]	303	5	6.37 (6.15-6.60)	3.40 (3.12-3.71)	5.72 (5.51-5.93)	1.86	7.33 (7.09-7.57)	8.14 (7.86-8.43)	9.98 (9.56-10.42)
A(H1N1)pdm09 (overall) [§]	512	10	7.39 (7.27-7.51)	5.43 (5.07-5.81)	6.81 (6.69-6.94)	1.45	8.07 (7.94-8.20)	8.62 (8.47-8.76)	9.79 (9.59-10.00)
SARS-CoV-2 (adult) [§]	3,575	20	7.00 (6.93-7.07)	3.48 (3.39-3.57)	6.27 (6.21-6.34)	2.03	8.02 (7.95-8.10)	8.89 (8.81-8.98)	10.86 (10.72-10.99)
SARS-CoV-2 (pediatric) [§]	198	9	7.43 (7.14-7.74)	3.63 (3.25-4.05)	6.69 (6.40-6.97)	2.06	8.47 (8.15-8.80)	9.35 (8.98-9.73)	11.32 (10.76-11.90)
SARS-CoV-2 (symptomatic/presymptomatic) [§]	1,574	22	7.40 (7.30-7.51)	3.81 (3.67-3.97)	6.68 (6.58-6.79)	2.00	8.39 (8.28-8.50)	9.21 (9.09-9.34)	11.05 (10.86-11.24)
SARS-CoV-2 (asymptomatic) [§]	2,221	7	6.72 (6.63-6.81)	3.33 (3.22-3.44)	6.01 (5.92-6.09)	2.01	8.04 (7.96-8.11)	8.91 (8.83-9.00)	10.88 (10.75-11.01)
SARS-CoV-2 (all DFSO) [§]	955	21	7.07 (6.94-7.21)	3.50 (3.33-3.68)	6.35 (6.22-6.48)	2.03	8.10 (7.95-8.25)	8.97 (8.80-9.15)	10.94 (10.68-11.21)
SARS-CoV-2 (-3 DFSO)	1	1	-	-	10.34	-	-	-	-
SARS-CoV-2 (-2 DFSO)	3	2	-	-	4.22 (2.41-6.02)	1.59	-	-	-
SARS-CoV-2 (-1 DFSO)	15	5	6.17 (5.11-7.47)	2.82 (1.89-4.19)	5.48 (4.25-6.70)	2.21	7.31 (6.11-8.75)	8.30 (6.88-10.02)	10.62 (8.38-13.45)
SARS-CoV-2 (0 DFSO)	50	11	6.66 (6.13-7.24)	3.52 (2.87-4.32)	6.00 (5.49-6.51)	1.83	7.62 (7.05-8.25)	8.44 (7.78-9.16)	10.28 (9.30-11.36)
SARS-CoV-2 (1 DFSO)	63	11	7.86 (7.33-8.43)	3.71 (3.04-4.53)	7.08 (6.54-7.63)	2.22	8.94 (8.36-9.55)	9.84 (9.17-10.56)	11.86 (10.84-12.99)
SARS-CoV-2 (2 DFSO)	71	15	7.33 (6.84-7.87)	3.46 (2.85-4.19)	6.58 (6.07-7.10)	2.22	8.42 (7.87-9.01)	9.34 (8.69-10.03)	11.41 (10.39-12.53)
SARS-CoV-2 (3 DFSO)	75	17	7.24 (6.73-7.78)	3.25 (2.70-3.92)	6.47 (5.95-6.98)	2.28	8.38 (7.81-8.98)	9.35 (8.68-10.07)	11.57 (10.52-12.72)
SARS-CoV-2 (4 DFSO)	85	17	6.83 (6.29-7.41)	2.75 (2.32-3.27)	6.06 (5.54-6.58)	2.44	8.12 (7.51-8.77)	9.25 (8.52-10.03)	11.90 (10.72-13.20)
SARS-CoV-2 (5 DFSO)	93	16	7.16 (6.69-7.66)	3.17 (2.69-3.73)	6.41 (5.95-6.87)	2.26	8.32 (7.80-8.87)	9.31 (8.70-9.97)	11.59 (10.63-12.64)
SARS-CoV-2 (6 DFSO)	105	15	6.84 (6.41-7.29)	3.13 (2.67-3.66)	6.10 (5.68-6.53)	2.23	7.96 (7.49-8.46)	8.93 (8.36-9.53)	11.14 (10.24-12.12)
SARS-CoV-2 (7 DFSO)	136	20	6.59 (6.23-6.97)	3.11 (2.71-3.56)	5.90 (5.55-6.26)	2.12	7.68 (7.27-8.11)	8.62 (8.14-9.13)	10.77 (10.05-11.60)
SARS-CoV-2 (8 DFSO)	123	19	6.51 (6.12-6.92)	3.03 (2.62-3.49)	5.82 (5.44-6.19)	2.13	7.62 (7.18-8.08)	8.58 (8.06-9.12)	10.78 (9.96-11.67)
SARS-CoV-2 (9 DFSO)	128	19	6.26 (5.87-6.67)	2.87 (2.50-3.29)	5.57 (5.20-5.94)	2.14	7.38 (6.95-7.85)	8.37 (7.85-8.92)	10.66 (9.83-11.55)
SARS-CoV-2 (10 DFSO)	115	18	5.71 (5.30-6.16)	2.55 (2.20-2.95)	5.09 (4.70-5.48)	2.14	6.89 (6.41-7.40)	7.93 (7.35-8.56)	10.41 (9.45-11.47)

*These two columns summarize the cumulative number of specimens (left) collected from the number of contributing studies (right) for each category in the systematic dataset.

[†]The mean and sample SD were calculated on the entirety of individual sample data for each category. These data were collected from studies clearly reporting data for individual specimens.

[‡]The Weibull quantile distributions were used to determine rVLs at the 80th, 90th and 99th cps.

[§]These categories included only rVL data from positive (above the detection limit) assay measurements.

^{||}Data for earlier DFSO were excluded from distribution fitting based on limited data, and empty cells were marked with "-".

[¶]These categories included negative assay measurements (set at the detection limit to estimate rVLs; N = 5, 3, 7, 10, 13, 17, 14, 22 and 17 specimens for 2-10 DFSO, respectively) for cases that tested positive at an earlier DFSO.

322
323
324
325
326
327
328

329 **Table S8.** Model parameters describing SARS-CoV-2 kinetics during respiratory
330 infection.

Parameter	Description	Value (95% CI)	Units
β	Infection rate constant	3.26 (2.21-4.31)	$\times 10^{-7}$ (copies/ml) ⁻¹ day ⁻¹
ρ	Cellular shedding rate of virus	1.33 (0.74-1.93)	copies/ml day ⁻¹ cell ⁻¹
c	Clearance rate of virus	3.30 (0.25-6.34)	day ⁻¹
δ	Clearance rate of infected epithelial cells	0.71 (0.26-1.15)	day ⁻¹
$R_{0,c}$	Cellular basic reproductive number	9.25	unitless

331

Table S9. Assessment of risk of bias based on the hybrid JBI critical appraisal checklist.

Study	Checklist items*									
	1	2	3	4	5	6	7	8	9	10
Argyropoulos et al. (76)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Baggio et al. (74)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Fajnzyblber et al. (65)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Han et al. (84)	Red	Green	Red	Green	Green	Green	Green	Green	Green	Green
Han et al. (82)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Hung et al. (70)	Green	Green	Red	Green	Green	Green	Green	Green	Green	Green
Hurst et al. (81)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Iwasaki et al. (71)	Yellow	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Kawasuji et al. (85)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
L'Huillier et al. (53)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Lavezzo et al. (42)	Green	Green	Red	Green	Green	Green	Green	Green	Green	Green
Lennon et al. (67)	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green
Lucas et al. (75)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Mitja et al. (77)	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green
Pan et al. (83)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Peng et al. (63)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Perera et al. (72)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Shi et al. (69)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Shrestha et al. (68)	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green
To et al. (43)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
van Kampen et al. (38)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Vetter et al. (78)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Wölfel et al. (21)	Green	Green	Red	Yellow	Green	Green	Green	Green	Green	Green
Wyllie et al. (73)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Xu et al. (80)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Yonker et al. (79)	Green	Green	Red	Yellow	Green	Green	Green	Green	Green	Green
Zhang et al. (62)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Zheng et al. (66)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Zou et al. (64)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Chen et al. (87)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Chu et al. (88)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Chu et al. (89)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Cheng et al. (91)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Hung et al. (90)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Peiris et al. (92)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Poon et al. (86)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Poon et al. (44)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Alves et al. (114)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Chan et al. (105)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Cheng et al. (115)	Green	Red	Green	Green	Green	Green	Green	Green	Green	Green
Cowling et al. (112)	Green	Green	Red	Yellow	Green	Green	Green	Green	Green	Green
Duchamp et al. (118)	Green	Green	Red	Yellow	Green	Green	Green	Green	Green	Green
Esposito et al. (109)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Hung et al. (106)	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green
Ip et al. (97)	Green	Green	Red	Yellow	Green	Green	Green	Green	Green	Green
Ito et al. (108)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Killingley et al. (103)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Launes et al. (102)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Lee et al. (104)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Lee et al. (110)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Li et al. (95)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Li et al. (111)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Loeb et al. (93)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Lu et al. (96)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Meschi et al. (99)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Ngaosuwanikul et al. (116)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Rath et al. (98)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Suess et al. (94)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Thai et al. (107)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
To et al. (117)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
To et al. (113)	Green	Green	Yellow	Yellow	Green	Green	Green	Green	Green	Green
Watanabe et al. (119)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Wu et al. (100)	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Yang et al. (101)	Green	Red	Yellow	Yellow	Green	Green	Green	Green	Green	Green

*Descriptions of each item are included in the hybrid JBI critical appraisal checklist (SI Appendix, Table S10). References before 58 are listed in the main body. Green, yellow and red represent yes, unclear and no, respectively.

335 **Table S10.** Hybrid JBI critical appraisal checklist

336 Reviewer _____ Date _____

337

338 Author _____ Year _____ Record Number _____

339

340

	Yes	No	Unclear	Not applicable
1. Was the sample frame appropriate to address the target population?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Were the study subjects and the setting described in detail?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability-based sampling for cross-sectional studies?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Was the response rate adequate, and if not, was the low response rate managed appropriately?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Was the sample size adequate?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were valid methods used for the identification of the condition?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were standard, valid methods used for measurement of the exposure?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was the exposure measured in an objective, reliable way for all participants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Was there clear reporting of clinical information of the participants?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Was statistical analysis appropriate?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

341

342 Overall appraisal: Include Exclude Seek further info

343 Comments (Including reason for exclusion)

344 _____

345 _____

346 _____

347 **Tool Guidance**

348 This hybrid checklist was based on the JBI Critical Appraisal Checklists for case series,
349 prevalence studies and analytical cross-sectional studies.

350

351 **1. Was the sample frame appropriate to address the target population?**

352 This question relies upon knowledge of the broader characteristics of the
353 population of interest and the geographical area.

354 This study broadly investigates the respiratory viral load for the diseases of
355 interest. The population of interest is the general population infected with
356 SARS-CoV-2, SARS-CoV-1, or A(H1N1)pdm09. The geographical area is
357 not constrained. Sample frames restricted to particular subgroups within the
358 general infected population were considered appropriate if they targeted one
359 of the following groups analysed in our study: asymptomatic,
360 presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized,
361 or community.

362

363 **2. Were the study subjects and the setting described in detail?**

364 Certain diseases or conditions vary in prevalence across different geographic
365 regions and populations (e.g. Women vs. Men, sociodemographic variables
366 between countries). The study sample should be described in sufficient detail
367 so that other researchers can determine if it is comparable to the population of
368 interest to them

369

370 **3. Did the study have consecutive inclusion of participants for case series
371 and cohort studies? Did the study use probability sampling for cross-
372 sectional studies?**

373 Inclusion of consecutive participants for case series and cohort studies yields
374 results at lower risk of bias compared to other sampling methods for these
375 study designs. Use of probability-based sampling methods for cross-sectional
376 studies yields estimates at lower risk of bias compared to other sampling
377 methods for this design. Studies that indicate a consecutive inclusion are more
378 reliable than those that do not. For example, a case series that states ‘we
379 included all patients (24) with osteosarcoma who presented to our clinic
380 between March 2005 and June 2006’ is more reliable than a study that simply
381 states ‘we report a case series of 24 people with osteosarcoma.’

382

383 **4. Was the response rate adequate, and if not, was the low response rate
384 managed appropriately?**

385 A large number of dropouts, refusals or “not founds” amongst selected
386 subjects may diminish a study’s validity, as can a low response rates for
387 survey studies. The authors should clearly discuss the response rate and any
388 reasons for non-response and compare persons in the study to those not in the

389 study, particularly with regards to their socio-demographic characteristics. If
390 reasons for non-response appear to be unrelated to the outcome measured and
391 the characteristics of non-responders are comparable to those who do respond
392 in the study, the researchers may be able to justify a more modest response
393 rate.

394

395 **5. Was the sample size adequate?**

396 The larger the sample, the narrower will be the confidence interval around the
397 prevalence estimate, making the results more precise. An adequate sample size
398 is important to ensure good precision of the final estimate. The sample size
399 threshold was calculated as follows:

400

$$n^* = z^2 \sigma / d^2$$

401 where n^* is the sample size threshold, z is the z-score for the level of confidence
402 (95%), σ is the standard deviation (assumed to be 3 log₁₀ copies/ml, a fourth of
403 the full range of rVLS) and d is the marginal error (assumed to be 1 log₁₀
404 copies/ml, based on the minimum detection limit for qRT-PCR across studies).
405 This item was met if ≥75% of the included DFSO had ≥46 specimen
406 measurements.

407

408 **6. Were valid methods used for the identification of the condition?**

409 Many health problems are not easily diagnosed or defined and some measures
410 may not be capable of including or excluding appropriate levels or stages of
411 the health problem. If the outcomes were assessed based on existing
412 definitions or diagnostic criteria, then the answer to this question is likely to
413 be yes. If the outcomes were assessed using observer reported, or self-reported
414 scales, the risk of over- or under-reporting is increased, and objectivity is
415 compromised. Importantly, determine if the measurement tools used were
416 validated instruments as this has a significant impact on outcome assessment
417 validity.

418

419 **7. Were standard, valid methods used for measurement of the exposure?**

420 The study should clearly describe the method of measurement of exposure.
421 Assessing validity requires that a 'gold standard' is available to which the
422 measure can be compared. The validity of exposure measurement usually
423 relates to whether a current measure is appropriate or whether a measure of
424 past exposure is needed.

425 In this study, standard methods to measure viral load in respiratory specimens
426 are RT-PCR quantifying via one of the standard genes for each virus.

427

428 **8. Was the exposure measured in an objective, reliable way for all**
429 **participants?**

430 The study should clearly describe the procedural aspects of the measurement
431 of exposure as well as factors that can contribute to heterogeneity in
432 measurement.

433 In this study, objective, reliable interpretation of the exposure depends on the
434 use of quantitative calibration; the specification of extraction; determination
435 of the viral load as a standard metric (e.g., copies/ml or equivalent) or in a
436 manner that can be converted to a standard metric; and, if present,
437 specification of the amount of diluent (e.g., viral transport media) used.

438

439 **9. Was there clear reporting of clinical information of the participants?**

440 There should be clear reporting of clinical information of the participants such
441 as the following information where relevant: disease status, comorbidities,
442 stage of disease, previous interventions/treatment, results of diagnostic tests,
443 etc.

444 In addition, there should be clear reporting of the number and types
445 (asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized,
446 non-hospitalized, community, etc.) of cases for measurements within the
447 sampling periods of interest. For studies that include data outside of the
448 infectious period, there should be clear reporting of clinical information for
449 participants for the specimen measurements that were collected from within
450 the infectious period.

451

452 **10. Was statistical analysis appropriate?**

453 As with any consideration of statistical analysis, consideration should be
454 given to whether there was a more appropriate alternate statistical method that
455 could have been used. The methods section of studies should be detailed
456 enough for reviewers to identify which analytical techniques were used and
457 whether these were suitable.

458

Risk of bias for each study	
Low	The majority of critical appraisal criteria are met ($\geq 6/10$ items). The estimates are likely to be correct for the target population.
High	The majority of critical appraisal criteria are not met ($< 6/10$ items). This may impact on the validity and reliability of the estimates. The estimates may not be correct for the target population.
Unclear	The majority of items are unclear. There was insufficient information to assess the risk of bias.

459

460

461 **SI References**

462

- 463 58. Z. Munn *et al.*, Methodological quality of case series studies: an introduction to
464 the JBI critical appraisal tool. *JBI Database System Rev Implement Rep*
465 10.11124/JBISRIR-D-19-00099 (2019).
- 466 59. S. Moola *et al.*, "Chapter 7: systematic reviews of etiology and risk" in Joanna
467 Briggs Institute Reviewer's Manual. The Joanna Briggs Institute, E. Aromataris,
468 Z. Munn, Eds. (The Joanna Briggs Institute, 2020).
- 469 60. Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance
470 for systematic reviews of observational epidemiological studies reporting
471 prevalence and cumulative incidence data. *Int J Evid Based Healthc* **13**, 147-153
472 (2015).
- 473 61. K. M. Johnston, P. Lakzadeh, B. M. K. Donato, S. M. Szabo, Methods of sample
474 size calculation in descriptive retrospective burden of illness studies. *BMC Med.*
475 *Res. Methodol.* **19**, 9 (2019).
- 476 62. N. Zhang *et al.*, Comparative study on virus shedding patterns in nasopharyngeal
477 and fecal specimens of COVID-19 patients. *Sci China Life Sci* 10.1007/s11427-
478 020-1783-9 (2020).
- 479 63. L. Peng *et al.*, SARS-CoV-2 can be detected in urine, blood, anal swabs, and
480 oropharyngeal swabs specimens. *J. Med. Virol.* 10.1002/jmv.25936 (2020).
- 481 64. L. Zou *et al.*, SARS-CoV-2 viral load in upper respiratory specimens of infected
482 patients. *N. Engl. J. Med.* **382**, 1177-1179 (2020).
- 483 65. J. Fajnzylber *et al.*, SARS-CoV-2 viral load is associated with increased disease
484 severity and mortality. *Nat Commun* **11**, 5493 (2020).

- 485 66. S. Zheng *et al.*, Viral load dynamics and disease severity in patients infected with
486 SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
487 cohort study. *BMJ* **369**, m1443 (2020).
- 488 67. N. J. Lennon *et al.*, Comparison of viral levels in individuals with or without
489 symptoms at time of COVID-19 testing among 32,480 residents and staff of
490 nursing homes and assisted living facilities in Massachusetts.
491 medRxiv:10.1101/2020.07.20.20157792 (2020).
- 492 68. N. K. Shrestha *et al.*, Distribution of transmission potential during nonsevere
493 COVID-19 illness. *Clin. Infect. Dis.* 10.1093/cid/ciaa886 (2020).
- 494 69. F. Shi *et al.*, Association of viral load with serum biomarkers among COVID-19
495 cases. *Virology* **546**, 122-126 (2020).
- 496 70. I. F. Hung *et al.*, Triple combination of interferon beta-1b, lopinavir-ritonavir, and
497 ribavirin in the treatment of patients admitted to hospital with COVID-19: an
498 open-label, randomised, phase 2 trial. *Lancet* **395**, 1695-1704 (2020).
- 499 71. S. Iwasaki *et al.*, Comparison of SARS-CoV-2 detection in nasopharyngeal swab
500 and saliva. *J. Infect.* **81**, e145-e147 (2020).
- 501 72. R. Perera *et al.*, SARS-CoV-2 virus culture and subgenomic RNA for respiratory
502 specimens from patients with mild coronavirus disease. *Emerg. Infect. Dis.* **26**,
503 2701-2704 (2020).
- 504 73. A. L. Wyllie *et al.*, Saliva or nasopharyngeal swab specimens for detection of
505 SARS-CoV-2. *N. Engl. J. Med.* **383**, 1283-1286 (2020).

- 506 74. S. Baggio *et al.*, SARS-CoV-2 viral load in the upper respiratory tract of children
507 and adults with early acute COVID-19. *Clin. Infect. Dis.* 10.1093/cid/ciaa1157
508 (2020).
- 509 75. C. Lucas *et al.*, Longitudinal analyses reveal immunological misfiring in severe
510 COVID-19. *Nature* **584**, 463-469 (2020).
- 511 76. K. V. Argyropoulos *et al.*, Association of initial viral load in severe acute
512 respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and
513 symptoms. *Am. J. Pathol.* **190**, 1881-1887 (2020).
- 514 77. O. Mitja *et al.*, Hydroxychloroquine for early treatment of adults with mild Covid-
515 19: a randomized-controlled trial. *Clin. Infect. Dis.* 10.1093/cid/ciaa1009 (2020).
- 516 78. P. Vetter *et al.*, Daily viral kinetics and innate and adaptive immune responses
517 assessment in COVID-19: a case series. *mSphere* 10.1128/mSphere.00827-20
518 (2020).
- 519 79. L. M. Yonker *et al.*, Pediatric severe acute respiratory syndrome coronavirus 2
520 (SARS-CoV-2): clinical Presentation, infectivity, and immune responses. *J.*
521 *Pediatr.* 10.1016/j.jpeds.2020.08.037 (2020).
- 522 80. Y. Xu *et al.*, Characteristics of pediatric SARS-CoV-2 infection and potential
523 evidence for persistent fecal viral shedding. *Nat. Med.* **26**, 502-505 (2020).
- 524 81. J. H. Hurst *et al.*, SARS-CoV-2 infections among children in the biospecimens
525 from respiratory virus-exposed kids (BRAVE Kids) Study. medRxiv:
526 10.1101/2020.08.18.20166835 (2020).

- 527 82. M. S. Han *et al.*, Viral RNA load in mildly symptomatic and asymptomatic
528 children with COVID-19, Seoul, South Korea. *Emerg. Infect. Dis.* **26**, 2497-2499
529 (2020).
- 530 83. Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, Q. Wang, Viral load of SARS-CoV-2
531 in clinical samples. *Lancet Infect. Dis.* **20**, 411-412 (2020).
- 532 84. M. S. Han *et al.*, Sequential analysis of viral load in a neonate and her mother
533 infected with SARS-CoV-2. *Clin. Infect. Dis.* 10.1093/cid/ciaa447 (2020).
- 534 85. H. Kawasuji *et al.*, Viral load dynamics in transmissible symptomatic patients
535 with COVID-19. medRxiv:10.1101/2020.06.02.20120014 (2020).
- 536 86. L. L. M. Poon *et al.*, Early diagnosis of SARS Coronavirus infection by real time
537 RT-PCR. *J. Clin. Virol.* **28**, 233-238 (2003).
- 538 87. W. J. Chen *et al.*, Nasopharyngeal shedding of severe acute respiratory syndrome-
539 associated coronavirus is associated with genetic polymorphisms. *Clin. Infect.*
540 *Dis.* **42**, 1561-1569 (2006).
- 541 88. C. M. Chu *et al.*, Role of lopinavir/ritonavir in the treatment of SARS: initial
542 virological and clinical findings. *Thorax* **59**, 252-256 (2004).
- 543 89. C. M. Chu *et al.*, Viral load distribution in SARS outbreak. *Emerg. Infect. Dis.* **11**,
544 1882-1886 (2005).
- 545 90. I. F. Hung *et al.*, Viral loads in clinical specimens and SARS manifestations.
546 *Emerg. Infect. Dis.* **10**, 1550-1557 (2004).
- 547 91. V. C. Cheng *et al.*, Viral replication in the nasopharynx is associated with diarrhea
548 in patients with severe acute respiratory syndrome. *Clin. Infect. Dis.* **38**, 467-475
549 (2004).

- 550 92. J. S. Peiris *et al.*, Clinical progression and viral load in a community outbreak of
551 coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**, 1767-
552 1772 (2003).
- 553 93. M. Loeb *et al.*, Longitudinal study of influenza molecular viral shedding in
554 Hutterite communities. *J. Infect. Dis.* **206**, 1078-1084 (2012).
- 555 94. T. Suess *et al.*, Shedding and transmission of novel influenza virus A/H1N1
556 infection in households--Germany, 2009. *Am. J. Epidemiol.* **171**, 1157-1164
557 (2010).
- 558 95. C. C. Li *et al.*, Correlation of pandemic (H1N1) 2009 viral load with disease
559 severity and prolonged viral shedding in children. *Emerg. Infect. Dis.* **16**, 1265-
560 1272 (2010).
- 561 96. P. X. Lu *et al.*, Relationship between respiratory viral load and lung lesion
562 severity: a study in 24 cases of pandemic H1N1 2009 influenza A pneumonia. *J.*
563 *Thorac. Dis.* **4**, 377-383 (2012).
- 564 97. D. K. M. Ip *et al.*, The dynamic relationship between clinical symptomatology
565 and viral shedding in naturally acquired seasonal and pandemic influenza virus
566 infections. *Clin. Infect. Dis.* **62**, 431-437 (2016).
- 567 98. B. Rath *et al.*, Virus load kinetics and resistance development during oseltamivir
568 treatment in infants and children infected with Influenza A(H1N1) 2009 and
569 Influenza B viruses. *Pediatr. Infect. Dis. J.* **31**, 899-905 (2012).
- 570 99. S. Meschi *et al.*, Duration of viral shedding in hospitalized patients infected with
571 pandemic H1N1. *BMC Infect. Dis.* **11**, 140 (2011).

- 572 100. U. I. Wu, J. T. Wang, Y. C. Chen, S. C. Chang, Severity of pandemic H1N1 2009
573 influenza virus infection may not be directly correlated with initial viral load in
574 upper respiratory tract. *Influenza Other Respir Viruses* **6**, 367-373 (2012).
- 575 101. J. R. Yang, J. Lo, Y. L. Ho, H. S. Wu, M. T. Liu, Pandemic H1N1 and seasonal
576 H3N2 influenza infection in the human population show different distributions of
577 viral loads, which substantially affect the performance of rapid influenza tests.
578 *Virus Res.* **155**, 163-167 (2011).
- 579 102. C. Launes *et al.*, Viral load at diagnosis and influenza A H1N1 (2009) disease
580 severity in children. *Influenza Other Respi. Viruses* **6**, e89-e92 (2012).
- 581 103. B. Killingley *et al.*, Virus shedding and environmental deposition of novel A
582 (H1N1) pandemic influenza virus: interim findings. *Health Technol. Assess.* **14**,
583 237-354 (2010).
- 584 104. N. Lee *et al.*, Viral clearance and inflammatory response patterns in adults
585 hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. *Antivir.*
586 *Ther.* **16**, 237-247 (2011).
- 587 105. P. K. Chan *et al.*, Clinical and virological course of infection with haemagglutinin
588 D222G mutant strain of 2009 pandemic influenza A (H1N1) virus. *J. Clin. Virol.*
589 **50**, 320-324 (2011).
- 590 106. I. F. Hung *et al.*, Effect of clinical and virological parameters on the level of
591 neutralizing antibody against pandemic influenza A virus H1N1 2009. *Clin.*
592 *Infect. Dis.* **51**, 274-279 (2010).

- 593 107. P. Q. Thai *et al.*, Pandemic H1N1 virus transmission and shedding dynamics in
594 index case households of a prospective Vietnamese cohort. *J. Infect.* **68**, 581-590
595 (2014).
- 596 108. M. Ito *et al.*, Detection of pandemic influenza A (H1N1) 2009 virus RNA by real-
597 time reverse transcription polymerase chain reaction. *Pediatr. Int.* **54**, 959-962
598 (2012).
- 599 109. S. Esposito *et al.*, Viral shedding in children infected by pandemic A/H1N1/2009
600 influenza virus. *Virology* **8**, 349 (2011).
- 601 110. C. K. Lee *et al.*, Comparison of pandemic (H1N1) 2009 and seasonal influenza
602 viral loads, Singapore. *Emerg. Infect. Dis.* **17**, 287-291 (2011).
- 603 111. I. W. Li *et al.*, The natural viral load profile of patients with pandemic 2009
604 influenza A(H1N1) and the effect of oseltamivir treatment. *Chest* **137**, 759-768
605 (2010).
- 606 112. B. J. Cowling *et al.*, Comparative epidemiology of pandemic and seasonal
607 influenza A in households. *N. Engl. J. Med.* **362**, 2175-2184 (2010).
- 608 113. K. K. To *et al.*, Viral load in patients infected with pandemic H1N1 2009
609 influenza A virus. *J. Med. Virology* **82**, 1-7 (2010).
- 610 114. V. R. G. Alves *et al.*, Influenza A(H1N1)pdm09 infection and viral load analysis
611 in patients with different clinical presentations. *Mem. Inst. Oswaldo Cruz* **115**,
612 e200009 (2020).
- 613 115. P. K. Cheng *et al.*, Performance of laboratory diagnostics for the detection of
614 influenza A(H1N1)v virus as correlated with the time after symptom onset and
615 viral load. *J. Clin. Virology* **47**, 182-185 (2010).

- 616 116. N. Ngaosuwanikul *et al.*, Influenza A viral loads in respiratory samples collected
617 from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses.
618 *Virol J.* **7**, 75 (2010).
- 619 117. K. K. To *et al.*, Delayed clearance of viral load and marked cytokine activation in
620 severe cases of pandemic H1N1 2009 influenza virus infection. *Clin. Infect. Dis.*
621 **50**, 850-859 (2010).
- 622 118. M. B. Duchamp *et al.*, Pandemic A(H1N1)2009 influenza virus detection by real
623 time RT-PCR: is viral quantification useful? *Clin. Microbiol. Infect.* **16**, 317-321
624 (2010).
- 625 119. M. Watanabe, S. Nukuzuma, M. Ito, T. Ihara, Viral load and rapid diagnostic test
626 in patients with pandemic H1N1 2009. *Pediatr. Int.* **53**, 1097-1099 (2011).
- 627 120. H. Ikeda *et al.*, Quantifying the effect of Vpu on the promotion of HIV-1
628 replication in the humanized mouse model. *Retrovirology* **13**, 23 (2016).
- 629